

# Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/PE545482D468EN.html>

Date: January 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: PE545482D468EN

## Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Proto oncogene protein c-akt inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Proto oncogene protein c-akt inhibitors Understanding

#### Proto oncogene protein c-akt inhibitors: Overview

Protein kinase B (PKB), also known as Akt, is the collective name of a set of three serine/threonine-specific protein kinases that play key roles in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. There are three different genes that encode isoforms of Protein kinase B. These three genes are referred to as AKT1, AKT2, and AKT3 and encode the RAC alpha, beta, and gamma serine/threonine protein kinases respectively. Akt isoforms are overexpressed in a variety of human tumors, and, at the genomic level, are amplified in gastric adenocarcinomas (Akt1), ovarian (Akt2), pancreatic (Akt2) and breast (Akt2)

cancers. The Akt kinases regulate cellular survival and metabolism by binding and regulating many downstream effectors, e.g. Nuclear Factor- $\kappa$ B, Bcl-2 family proteins, master lysosomal regulator TFEB and murine double minute 2 (MDM2).

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Proto oncogene protein c-akt inhibitors R&D. The therapies under development are focused on novel approaches for Proto oncogene protein c-akt inhibitors.

## Proto oncogene protein c-akt inhibitors Emerging Drugs Chapters

This segment of the Proto oncogene protein c-akt inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Proto oncogene protein c-akt inhibitors Emerging Drugs

### MK 2206: Merck

MK-2206 is a drug candidate being investigated to help treat cancer. Its chemical formula is  $C_{25}H_{21}N_5O$ . It acts as an allosteric AKT inhibitor. It is a highly selective inhibitor of pan-Akt, namely, of all three Akt isoforms Akt1, Akt2, and Akt3. Currently, it is in Phase III stage of clinical trial evaluation to treat various cancers.

### Ipatasertib: Genentech

Ipatasertib is an oral, highly specific, investigational medicine designed to target and bind to all three isoforms of AKT, which blocks the PI3K/AKT signaling pathway and may prevent cancer cell growth and survival. Ipatasertib is being studied in tumors that are frequently found to have activation of the PI3K/AKT pathway, including breast and prostate cancers. Clinical studies are ongoing to evaluate the efficacy and safety of ipatasertib and the opportunity it may provide to address significant unmet needs for

patients with these diseases. Currently, it is in Phase III stage of development to treat breast and prostate cancer.

Further product details are provided in the report.....

Proto oncogene protein c-akt inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Proto oncogene protein c-akt inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Proto oncogene protein c-akt inhibitors

There are approx. 14+ key companies which are developing the Proto oncogene protein c-akt inhibitors. The companies which have their Proto oncogene protein c-akt inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Genentech.

Phases

DelveInsight's report covers around 14+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Proto oncogene protein c-akt inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been

categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Proto oncogene protein c-akt inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Proto oncogene protein c-akt inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto oncogene protein c-akt inhibitors drugs.

Proto oncogene protein c-akt inhibitors Report Insights

Proto oncogene protein c-akt inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Proto oncogene protein c-akt inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

## Current Scenario and Emerging Therapies:

How many companies are developing Proto oncogene protein c-akt inhibitors drugs?

How many Proto oncogene protein c-akt inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proto oncogene protein c-akt inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Proto oncogene protein c-akt inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Proto oncogene protein c-akt inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Merck

Genentech

Signpath Pharma

Kazia Therapeutics

HUYA Bioscience International

AstraZeneca

Novartis Oncology

Aytu BioPharma

CURACLE

Almac Discovery

Taiho Pharmaceutical

Astex Pharmaceuticals

Prescient Therapeutics

Laekna Therapeutics

Tactical Therapeutics

## Key Products

MK 2206

Ipatasertib

Curcumin liposomal

Paxalisib

Tucidinostat

Capivasertib

Miransertib

Afuresertib

Enzastaurin

CU 05

API-2

Pravitinib

Uprosertib

ALM 301

ARQ 751

TAS 0612

AT 13148



## Contents

- Introduction
- Executive Summary
- Proto oncogene protein c-akt inhibitors: Overview
  - Structure
  - Mechanism of Action
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Proto oncogene protein c-akt inhibitors – DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
  - Comparative Analysis
- Ipatasertib: Genentech
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- MK 2206: Merck
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
  - Comparative Analysis
- ARQ 751: Merck & Co
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products

Comparative Analysis  
CU 05: CURACLE  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
Comparative Analysis  
Proto oncogene protein c-akt inhibitors Key Companies  
Proto oncogene protein c-akt inhibitors Key Products  
Proto oncogene protein c-akt inhibitors- Unmet Needs  
Proto oncogene protein c-akt inhibitors- Market Drivers and Barriers  
Proto oncogene protein c-akt inhibitors- Future Perspectives and Conclusion  
Proto oncogene protein c-akt inhibitors Analyst Views  
Proto oncogene protein c-akt inhibitors Key Companies  
Appendix

## I would like to order

Product name: Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/PE545482D468EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PE545482D468EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970